Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Aeolus Pharmaceuticals, Inc. (AOLS) since 2010 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Aeolus Pharmaceuticals, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1261734.
Total stock buying since 2010: $134,326.
Total stock sales since 2010: $3,118,985.
Total stock option exercises since 2010: $0.
▪ Recent SEC 13D filings for all companies
▪ Recent portfolio reports of all companies
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2013 | 410,000 | $3,500 | 1,793,894 | $591,985 | 0 | $0 |
| 2012 | 340,360 | $101,678 | 0 | $0 | 0 | $0 |
| 2011 | 60,300 | $29,148 | 4,057,214 | $2,527,000 | 0 | $0 |
| 2010 | 5,000,000 | $0 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2013-03 | 10,000 | $3,500 | 0 | $0 | 0 | $0 |
| 2013-02 | 400,000 | $0 | 1,793,894 | $591,985 | 0 | $0 |
| 2012-05 | 7,027 | $1,679 | 0 | $0 | 0 | $0 |
| 2012-04 | 333,333 | $99,999 | 0 | $0 | 0 | $0 |
| 2011-05 | 50,300 | $21,738 | 0 | $0 | 0 | $0 |
| 2011-03 | 10,000 | $7,410 | 3,992,614 | $2,464,478 | 0 | $0 |
| 2011-02 | 0 | $0 | 64,600 | $62,522 | 0 | $0 |
| 2010-08 | 5,000,000 | $0 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2013-03-06 | Mcmanus John L (President and CEO) | Buy | 10,000 | .35 | 3,500 |
| 2013-02-19 | Xmark Opportunity Partners, Llc | Sale | 1,793,894 | .33 | 591,985 |
| 2013-02-19 | Krivulka Joseph J (Director) | Buy | 400,000 | .00 | 0 |
| 2012-05-23 | Skibsted Russell (Chief Financial Officer) | Buy | 7,027 | .24 | 1,679 |
| 2012-04-05 | Krivulka Joseph J (Director) | Buy | 333,333 | .30 | 99,999 |
| 2011-05-24 | Mcmanus John L (President and CEO) | Buy | 10,300 | .46 | 4,738 |
| 2011-05-18 | Skibsted Russell (Chief Financial Officer) | Buy | 20,000 | .42 | 8,400 |
| 2011-05-18 | Mcmanus John L (President and CEO) | Buy | 20,000 | .43 | 8,600 |
| 2011-03-16 | Efficacy Biotech Master Fund Ltd. | Sale | 3,799,380 | .61 | 2,317,621 |
| 2011-03-15 | Efficacy Biotech Master Fund Ltd. | Sale | 193,234 | .76 | 146,857 |
| 2011-03-15 | Mcmanus John L (President and CEO) | Buy | 10,000 | .74 | 7,410 |
| 2011-02-16 | Efficacy Biotech Master Fund Ltd. | Sale | 57,600 | .97 | 55,872 |
| 2011-02-15 | Efficacy Biotech Master Fund Ltd. | Sale | 7,000 | .95 | 6,650 |
| 2010-08-11 | Xmark Opportunity Partners, Llc (10% Owner) | Buy | 2,500,000 | .00 | 0 |
| 2010-08-11 | Cavalier David (Director) | Buy | 2,500,000 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises of AOLS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Aeolus Pharmaceuticals, Inc. (symbol AOLS, CIK number 1261734) see the Securities and Exchange Commission (SEC) website.